TY - JOUR
T1 - Alteration of serum N-glycan profile in patients with autoimmune pancreatitis
AU - Tomoda, Takeshi
AU - Nouso, Kazuhiro
AU - Kato, Hironari
AU - Miyahara, Koji
AU - Dohi, Chihiro
AU - Morimoto, Yuki
AU - Kinugasa, Hideaki
AU - Akimoto, Yutaka
AU - Matsumoto, Kazuyuki
AU - Yamamoto, Naoki
AU - Noma, Yasuhiro
AU - Horiguchi, Shigeru
AU - Tsutsumi, Koichiro
AU - Amano, Maho
AU - Nishimura, Shin Ichiro
AU - Yamamoto, Kazuhide
N1 - Funding Information:
TT received a research grant from the Pancreas Research Foundation of Japan ( 201410 ). KN received a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science and a research grant from the Japan Science and Technology Agency (JST) ( 23590976 ). SN received a research grant from the JST and the Ministry of Education, Culture, Science, and Technology, Japan ( 25220206 ). This work was supported by JSPS Core-to-Core Program, B. Asia–Africa Science Platforms.
Publisher Copyright:
Copyright © 2015, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved.
PY - 2016
Y1 - 2016
N2 - Objectives: The aims of this study were to determine the change in whole-serum N-glycan profile in autoimmune pancreatitis (AIP) patients and to investigate its clinical utility. Methods: We collected serum from 21 AIP patients before any treatment, and from 60 healthy volunteers (HLTs). Serum glycan profile was measured by comprehensive and quantitative high-throughput glycome analysis. Results: Of the 53 glycans detected, 14 were differentially expressed in AIP patients. Pathway analysis demonstrated that agalactosyl and monogalactosyl bi-antennary glycans were elevated in AIP patients. Among the 14 glycans, #3410, #3510, and #4510 showed high area under receiver operating characteristic (AUROC) values (0.955, 0.964, and 0.968 respectively) for the diagnosis of AIP. These three glycans were mainly bound to immunoglobulin G; however, their serum levels were significantly higher, even in AIP patients who showed lower serum IgG4 levels, than in HLTs. Conclusions: We demonstrated, for the first time, whole-serum glycan profiles of AIP patients and showed that the levels of glycans #3410, #3510, and #4510 were increased in AIP patients. These glycans might be valuable biomarkers of AIP.
AB - Objectives: The aims of this study were to determine the change in whole-serum N-glycan profile in autoimmune pancreatitis (AIP) patients and to investigate its clinical utility. Methods: We collected serum from 21 AIP patients before any treatment, and from 60 healthy volunteers (HLTs). Serum glycan profile was measured by comprehensive and quantitative high-throughput glycome analysis. Results: Of the 53 glycans detected, 14 were differentially expressed in AIP patients. Pathway analysis demonstrated that agalactosyl and monogalactosyl bi-antennary glycans were elevated in AIP patients. Among the 14 glycans, #3410, #3510, and #4510 showed high area under receiver operating characteristic (AUROC) values (0.955, 0.964, and 0.968 respectively) for the diagnosis of AIP. These three glycans were mainly bound to immunoglobulin G; however, their serum levels were significantly higher, even in AIP patients who showed lower serum IgG4 levels, than in HLTs. Conclusions: We demonstrated, for the first time, whole-serum glycan profiles of AIP patients and showed that the levels of glycans #3410, #3510, and #4510 were increased in AIP patients. These glycans might be valuable biomarkers of AIP.
KW - Autoimmune diseases
KW - Autoimmune pancreatitis (AIP)
KW - Bio marker
KW - Glycan biosynthesis
KW - Glycomics
KW - Serum glycans
UR - http://www.scopus.com/inward/record.url?scp=84951731283&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951731283&partnerID=8YFLogxK
U2 - 10.1016/j.pan.2015.11.002
DO - 10.1016/j.pan.2015.11.002
M3 - Article
C2 - 26723536
AN - SCOPUS:84951731283
SN - 1424-3903
VL - 16
SP - 44
EP - 51
JO - Pancreatology
JF - Pancreatology
IS - 1
ER -
